Quince Therapeutics (QNCX) News Today $1.68 -0.01 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 08/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) PT at $8.00July 24, 2025 | americanbankingnews.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by AnalystsJuly 21, 2025 | marketbeat.comBrookline Capital Management Comments on QNCX Q3 EarningsJuly 21, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral CapitalJuly 17, 2025 | marketbeat.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...July 12, 2025 | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesJune 26, 2025 | marketbeat.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18, 2025 | businesswire.comQuince Therapeutics raises $11.5 million in private placementJune 14, 2025 | investing.comQuince Therapeutics Raises $11.5M in Private PlacementJune 13, 2025 | tipranks.comQuince Therapeutics' (QNCX) Buy Rating Reaffirmed at D. Boral CapitalJune 13, 2025 | marketbeat.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12, 2025 | businesswire.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comQuince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026May 15, 2025 | seekingalpha.comQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finance.yahoo.comQuince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comQuince Therapeutics (QNCX) Expected to Announce Earnings on MondayMarch 31, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 33.5% in MarchMarch 30, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.comQuince Therapeutics (NASDAQ:QNCX) Given New $4.00 Price Target at D. Boral CapitalMarch 26, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Releases Earnings ResultsMarch 26, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Coverage Initiated by Analysts at OppenheimerMarch 25, 2025 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsMarch 24, 2025 | businesswire.comOppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform RecommendationMarch 24, 2025 | msn.comQuince Therapeutics (QNCX) Projected to Post Earnings on MondayMarch 22, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of "Buy" by AnalystsMarch 18, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by BrokeragesFebruary 21, 2025 | marketbeat.comQuince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaFebruary 7, 2025 | businesswire.comQuince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral CapitalFebruary 5, 2025 | marketbeat.comQuince Therapeutics gets USPTO notice of allowance in Ataxia-TelangiectasiaFebruary 4, 2025 | markets.businessinsider.comQuince Therapeutics secures USPTO nod for A-T treatment patentFebruary 4, 2025 | msn.comQuince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-TelangiectasiaFebruary 4, 2025 | businesswire.comQuince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-TelangiectasiaJanuary 27, 2025 | finance.yahoo.comQuince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory BoardJanuary 24, 2025 | finance.yahoo.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from AnalystsJanuary 2, 2025 | marketbeat.comQuince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral CapitalJanuary 2, 2025 | marketbeat.comBrookline Capital Management Predicts QNCX FY2024 EarningsDecember 20, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at BrooklineDecember 19, 2024 | msn.comBrookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationDecember 19, 2024 | msn.comBrookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)December 18, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short InterestDecember 16, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest UpdateNovember 29, 2024 | marketbeat.comQuince Therapeutics Share Price (QNCX.US)November 18, 2024 | lse.co.ukShort Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Increases By 23.0%November 15, 2024 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.com Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼-1.000.52▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼11▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Foghorn Therapeutics News Candel Therapeutics News Aura Biosciences News Abeona Therapeutics News Prothena News Astria Therapeutics News Altimmune News Amarin News Palvella Therapeutics News Rocket Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
